Cited 0 times in
결핵균에서 gyrA 유전자 돌연변이에 따른 fluoroquinolone계 약제들의 교차내성
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조상래 | - |
dc.date.accessioned | 2017-09-29T06:30:03Z | - |
dc.date.available | 2017-09-29T06:30:03Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 1738-3536 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/149862 | - |
dc.description.abstract | Background : Fluoroquinolone drugs are an important anti-tuberculous agent for the treatment of multi-drug resistant tuberculosis. However, many drugs belonging to the fluoroquinolones have different cross resistance to each other. Methods : Sixty-three ofloxacin (OFX) resistant and 10 pan-susceptible M. tuberculosis isolates were selected, and compared for their cross resistance using a proportion method on Lowenstein-Jensen media, containing ofloxacin (OFX), ciprofloxacin (CIP), levofloxacin (LVX), moxifloxacin (MXF), gatifloxacin (GAT) and sparfloxacin (SPX), at concentrations ranging from 0.5 to 3킽/ml. DNA extracted from the isolates was directly sequenced after amplifying from the gyrA and gyrB genes. Results : The 63 OFX resistant M. tuberculosis isolates showed complete cross resistance to CIP, but only 90.5, 44.4,36.5 and 46.0% to LVX, MXF, GAT, and to SPX, respectively. Fifty-one of the isolates (81.0%) had point mutations in codons 88, 90, 91 and 94 in gyrA, which are known to be correlated with OFX resistance. The Gly88Ala, Ala90Valand Asp94Ala mutations in gyrA showed a tendency to be susceptible to MXF, GAT and SPX. Only 4 isolates had mutations in the gyrB gene, which did not affect the OFX resistance. Conclusion : About 60% of the OFX resistant M. tuberculosis isolates were susceptible to GAT, SPX and MXF. These fluoroquinolones may be useful in the treatment of TB patients showing OFX resistance. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한결핵 및 호흡기학회 | - |
dc.relation.isPartOf | TUBERCULOSIS AND RESPIRATORY DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Mycobacterium tuberculosis | - |
dc.subject.MESH | Fluoroquinolones | - |
dc.subject.MESH | Cross resistance | - |
dc.subject.MESH | gyrA | - |
dc.subject.MESH | Genotypes | - |
dc.title | 결핵균에서 gyrA 유전자 돌연변이에 따른 fluoroquinolone계 약제들의 교차내성 | - |
dc.title.alternative | Cross Resistance of Fluoroquinolone Drugs on gyrA Gene Mutation in Mycobacterium tuberculosis | - |
dc.type | Article | - |
dc.publisher.location | Korea | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Microbiology (미생물학교실) | - |
dc.contributor.googleauthor | 박영길 | - |
dc.contributor.googleauthor | 박찬홍 | - |
dc.contributor.googleauthor | 고원중 | - |
dc.contributor.googleauthor | 권오정 | - |
dc.contributor.googleauthor | 김범준 | - |
dc.contributor.googleauthor | 국윤호 | - |
dc.contributor.googleauthor | 조상래 | - |
dc.contributor.googleauthor | 장철훈 | - |
dc.contributor.googleauthor | 배길한 | - |
dc.identifier.doi | OAK-2005-05313 | - |
dc.contributor.localId | A03824 | - |
dc.relation.journalcode | J02761 | - |
dc.identifier.eissn | 2005-6184 | - |
dc.relation.journalsince | 2004~ | - |
dc.relation.journalbefore | ~2004 Tuberculosis and Respiratory Diseases (결핵 및 호흡기질환) | - |
dc.subject.keyword | Mycobacterium tuberculosis | - |
dc.subject.keyword | Fluoroquinolones | - |
dc.subject.keyword | Cross resistance | - |
dc.subject.keyword | gyrA | - |
dc.subject.keyword | Genotypes | - |
dc.contributor.alternativeName | Cho, Sang Nae | - |
dc.citation.volume | 59 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 250 | - |
dc.citation.endPage | 256 | - |
dc.identifier.bibliographicCitation | TUBERCULOSIS AND RESPIRATORY DISEASES, Vol.59(3) : 250-256, 2005 | - |
dc.date.modified | 2017-05-04 | - |
dc.identifier.rimsid | 41955 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.